KM Research Hub
← 返回论文库
待处理 入排:待复核 图源:待检查 入排置信度 0.00

TL1A inhibitors in inflammatory bowel disease: A systematic review of phase 2 clinical trials.

Jeong-Gyu Choi, Eun Jeong Gong, Chang Seok Bang, Jae Jun Lee

Saudi J Gastroenterol 32(5) 379-393

PMID42726749
PMCIDPMC13630358
DOI10.4103/sjg.sjg_268_26
发表日期2026-09-11
入排依据:未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
摘要

摘要

BACKGROUND:: Tumor necrosis factor-like ligand 1A (TL1A) (TNFSF15) signals through DR3 to drive both mucosal inflammation and intestinal fibrosis. Three anti-TL1A antibodies (tulisokibart, afimkibart, and duvakitug) have completed Phase 2 trials in inflammatory bowel disease (IBD). We performed a systematic review (SR) of all Phase 2 data, with the meta-analysis focused on the three randomized controlled trials (RCTs) in ulcerative colitis (UC). METHODS:: PubMed, Embase, CENTRAL, and ClinicalTrials.gov were searched through January 2026. Risk of bias was assessed using RoB 2.0 and ROBINS-I. Risk ratios (RR), risk differences (RD), and number needed to treat (NNT) were pooled using random-effects models. RESULTS:: Six studies from five trials (three RCTs and two single-arm studies; 804 patients) were included. In UC, pooled RR versus placebo was 2.56 (95% CI 1.60–4.09; I² = 0.0%) for clinical remission and 2.13 (1.44–3.16; I² = 0.0%) for endoscopic improvement (both P < 0.001). Corresponding RDs were +22.2% (NNT 4.5) and +22.6% (NNT 4.4). Duvakitug showed a dose-response, with 900 mg approximately doubling the effect of 450 mg. In Crohn’s disease (CD), duvakitug 900 mg achieved endoscopic response RR 3.67 versus placebo (95% CI 1.64–8.20; RD +34.8%, NNT 2.9). Serious adverse event rates were numerically low and comparable to or lower than placebo across trials. GRADE certainty of evidence was moderate for UC efficacy outcomes. CONCLUSIONS:: Three structurally distinct anti-TL1A antibodies showed consistent Phase 2 efficacy signals in UC with zero between-study heterogeneity (I² = 0.0%), though, given only three UC RCTs and one CD RCT, this apparent class-level signal is underpowered for heterogeneity and remains tentative. Phase 3 trials are needed to confirm these preliminary findings.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。